Considering Clinical Readiness
Industry:
Biopharma, Cell and Gene Therapy
Type:
Video
As more cell and gene therapies (CGTs) progress to clinical stages, ensuring clinical readiness is critical for their successful adoption. However, significant barriers—ranging from manufacturing constraints to regulatory challenges—continue to slow down patient access.
In this expert discussion, Josh Ludwig (ScaleReady), Carol Houts (Germfree), Heather Purvis (Title21), and Priya Baraniak (Pluristyx) explore the urgent need for clinical readiness in cell and gene therapy delivery.
Our panelists discuss the key challenges faced by clinical centers, the importance of standardization, and how industry collaboration can accelerate patient access. By addressing these barriers, we can support the seamless integration of cell and gene therapies into healthcare systems and ensure that life-saving therapies reach patients faster.
Watch this insightful discussion to learn how the industry is working to advance clinical readiness and overcome obstacles to widespread CGT adoption.
You might also be interested in
Inside Germfree’s Isolator Engineering Process
Why Mobile and Modular Cleanrooms are Changing the Game in Bio-Manufacturing
Smarthood™: Setting a New Standard in IV Compounding
Contact us: Let's unlock your scientific potential together
Complete our contact form and a member of our commercial team will contact you within 24 hours.